spacer
home > epc > winter 2019 > improving quality using centralised statistical monitoring
PUBLICATIONS
European Pharmaceutical Contractor

Improving Quality Using Centralised Statistical Monitoring

As the dust begins to settle after the ICH Good Clinical Practice E6 (R2) Addendum, the importance of data oversight and integrity should still not be overlooked. It has become increasingly important to the FDA after the Addendum and likewise for the sponsor’s responsibility to ensure quality management over regulatory submissions.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Thomas Underwood, Marketing Manager at Quanticate, has over 10 years’ experience within the life sciences industry. Originally working in operations in both clinical data management and programming, he moved into the commercial division and has been in his current role for over eight years. An integral part of Thomas’ role is product development, involving extensive research into industry regulations and the resulting technology and services these influence, such as risk-based monitoring, data quality oversight, and centralised statistical monitoring. He has a postgraduate professional diploma with the Chartered Institute of Marketing and secured Chartered Marketer status in 2014.
spacer
Thomas Underwood
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera announces a better drug deposition with RetroNose to enhance therapeutic efficacy of nasal treatments

After announcing a partnership with the Research Center for Respiratory Diseases (CEPR) of Inserm/University of Tours in April 2017, Nemera is happy to publish enhanced drug deposition results compared to classic nasal sprays with RetroNose.
More info >>

White Papers

EU GDP Guidelines: Implications for Shipping Clinical Materials into the European Market

PCI Pharma Services

Recently, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) opened an investigation into a patient complaint of mold on paracetamol (acetaminophen) tablets (1). It discovered the product was shipped by sea from India to multiple companies in the UK at temperatures reaching up to 60 degrees Celsius. Labeling for paracetamol tablets typically states they should be kept below 30 degrees Celsius. In addition, MHRA discovered the humidity levels exceeded 80 percent during shipping, which is too high for the packaging that was used.
More info >>

 
Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement